ONYX-015 and the first tumor-selective adenoviruses (late 1990s)
Researchers deleted a gene from an adenovirus so it could only replicate in cells with faulty p53, a defect common in tumors. The virus, ONYX-015, was injected into head and neck cancers in trials through the late 1990s, often alongside chemotherapy.
Some injected tumors shrank, mainly when combined with chemotherapy, but the program did not reach approval.
Later tumor-selective viruses kept the design: a single genetic switch tied to a trait cancer cells share.
The Minnesota virus uses the same strategy with a different switch, driven by an enzyme called cyclooxygenase-2 that cancer cells carry at far higher levels than healthy tissue.
